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Is folic acid protective against neural tube defects in infants exposed to sodium valproate in utero? 
John J. Craig*, P. Morrison+, J.I. Morrow* & V.H. Patterson* 
*Department of Neurology, Royal Victoria Hospital, Belfast, UK; + Department of Medical Genetics, 
Be/fast City Hospital, Be/fast, UK 
The risk of neural tube defects (NTDs) in infants exposed to sodium valproate (VPA) in utero is estimated between 2% and 
6%. Since this is similar to the risk of a recurrent NTD for a woman who has had a previous child with this condition, and 
high-dose folic acid (4 mg) has been shown to be protective in this situation, it has been suggested that a similar dose (5 mg 
daily) of folic acid should be prescribed periconceptually to women taking VPA. There is, however, no evidence to support this. 
We present the case of an infant born with an NTD to a woman taking VPA despite maternal high-dose periconceptual folic 
acid intake to highlight the difficulties in counselling women with epilepsy who become pregnant whilst taking VPA based on 
current information. We also present the data so far collected through the UK Register, which we have set up to assess the relative 
safety of the AEDs, to demonstrate the low-level of periconceptual folic acid intake in women taking VPA. Further randomized 
studies need to be done to compare the protective effect of low and high-dose folic acid in women taking AEDs. In the meantime, 
however, all those dealing with patients with epilepsy should ensure that folic acid is taken by their female patients who are 
planning a pregnancy. 
The antiepileptic drugs in pregnancy-a register in the UK to determine the relative safety of each 
in this situation 
John Craig*, Aline RussetIt, Patrick Morrison:, Linda Parsons” & Jim Morrow* 
* Department of Neurology, Royal Victoria Hospital, Be/fast, UK; + Department of Neurophysiology, 
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Counselling women with epilepsy as to the safest preparation in pregnancy has become more difficult in the last few years because 
of the ever increasing number of antiepileptic drugs (AEDs). This is because whilst the teratogenic potential of the older AEDs 
is well established, the situation for the newer drugs is unknown. Recognizing the problems with post-marketing surveillance 
in general, and existing registers in particular, we have established a register, in conjunction with the British Neurological 
Surveillance Unit, to which all pregnancies occurring in women with epilepsy in the UK can be reported. Since commencing 
the study approximately 30 months ago we have been informed of almost 400 cases, of which more than 80% have been 
prospectively reported, and have collected full follow-up details on almost half of these so far. We have therefore established an 
effective method of obtaining information, which in part, might allow the relative safety of each of the AEDs in pregnancy to be 
determined. We would therefore encourage all those dealing with women with epilepsy to refer suitable cases to the register so 
that this might be achieved. 
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